Alpha Teknova, Inc. revenue by segment TKNO

Annual Quarterly

Alpha Teknova, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Lab Essentials at $31.0 million, 77% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021
Revenue	46	41	38	37	41	37
Lab Essentials	33 +7.7% share 72.8%	31 +7.5% share 76.6%	29 +0.3% share 76.5%	29 -9.4% share 78.5%	32 +16.9% share 76.7%	27 share 73.7%
Clinical Solutions	10 +54.4% share 22.8%	8 +7.8% share 18.9%	7 +5.3% share 18.8%	7 -20.2% share 18.4%	8 +24.3% share 20.4%	7 share 18.4%
Other Product	2 +3.0% share 4.5%	2 +3.5% share 4.5%	2 +54.0% share 4.7%	1 -4.7% share 3.1%	1 -13.2% share 2.9%	1 share 3.8%
Sample Transport	—	—	—	—	—	2 share 4.1%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: TKNO (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Hollister, CA
SEC filer status: Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK: 1850902

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.